Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.56 |
| ▸ | CKS1B | P61024 | 2/20 | 0.50 |
| ▸ | SKP1 | P63208 | 2/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.50 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.50 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | ADK | P55263 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801741 | 0.95 | MAP4K4 (0.55) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL6052487 | 0.86 | MAP4K4 (0.56) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL26669649 | 0.85 | GPR119 (0.57) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL653950 | 0.84 | GPR119 (0.56) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL27035710 | 0.84 | GPR119 (0.56) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL30683399 | 0.84 | GPR119 (0.56) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL31540073 | 0.84 | GPR119 (0.56) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL622957 | 0.84 | GPR119 (0.56) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL18163269 | 0.84 | MAP4K4 (0.54) | MAP4K4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL14973123 | 0.83 | GPR119 (0.55) | MAP4K4GPR119CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184550-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-09-12 | — | — | WO | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| CN-108135175-B | Bicyclic compounds and their use for inhibition of SUV39H2 | 肿瘤疗法科学股份有限公司 | 2021-04-06 | — | — | CN | disclosed |
| EP-3355699-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE INC (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-20180273529-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | ONCOTHERAPY SCIENCE, INC. (JP) | 2018-09-27 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273529-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | SUV39H2, SUV39H1, EZH1 | MAP4K4 3939/4885GPR119 1105/4885CKS1B 2502/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | MAP4K4 1635/4885GPR119 136/4885CKS1B 541/4885 |
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | MAP4K4 79/4885GPR119 316/4885CKS1B 253/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | MAP4K4 79/4885GPR119 316/4885CKS1B 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.